$19.62
▼ -2.3% Today
as of Sep 4, 16:54 ET
Last 30 days
Recent Press Releases & News
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
UBS Adjusts Schrodinger PT to $19 From $13, Maintains Neutral Rating
Schrödinger (SDGR) Is Up 8.5% After AI Co‑Scientist Deal With BMS And Q2 Profitability Shift – Has The Bull Case Changed?
Overview
52-week range
$11
$23
72% of range
Avg surprise (last 3)
-10.4%
Avg reaction (last 2)
+0.2%
50% positive
Latest IV / EM
57%
EM ±8.9% · $20 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.08 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $-0.81 | $-0.56 | -44.6% | +1.2% | -0.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.45 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.59 | $-0.83 | +28.9% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-0.82 | $-0.71 | -15.5% | — | +0.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.52 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.74 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.76 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.86 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.06 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $1.75 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $59M | $59M | — | $54M | $55M | $60M | — | $35M |
| Cost of revenue | $26M | $29M | — | $26M | $29M | $28M | — | $18M |
| Gross profit | $32M | $30M | — | $28M | $26M | $31M | — | $18M |
| Operating income | $-42M | $-49M | — | $-46M | $-53M | $-51M | — | $-68M |
| Net income | $6M | $-60M | — | $-33M | $-43M | $-60M | — | $-38M |
| EPS (diluted) | $0.08 | $-0.81 | — | $-0.45 | $-0.59 | $-0.82 | — | $-0.52 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $288M | $260M | $231M | $172M | $220M | $326M | $147M | $160M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $470M | $464M | $519M | $472M | $514M | $571M | $635M | $456M |
| Total assets | $640M | $634M | $726M | $654M | $688M | $743M | $823M | $669M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $311M | $321M | $362M | $332M | $345M | $370M | $402M | $220M |
| Total equity | $329M | $314M | $364M | $321M | $343M | $374M | $421M | $449M |